Product logins

Find logins to all Clarivate products below.


Growth Hormone Deficiency | Treatment Algorithms: Claims Data Analysis | Growth Hormone Disorders | US | 2019

Growth hormone is an endogenous hormone produced by the pituitary gland; a deficiency in its production or activity is characterized by short stature, decreased capacity for exercise, and unfavorable changes in cardiovascular function. Avariety of recombinant human growth hormone (somatropin) brands are available to treat hypopituitarism, short stature, and rare genetic disorders. The choice of growth hormone product typically depends on the product’s delivery system and the support package offered by the manufacturer. This U.S. claims data analysis covers prescription patterns in growth hormone deficiency and other disorders for which recombinant growth hormone is approved for use.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed growth hormone deficiency patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed growth hormone deficiency patients?
  • How has Omnitrope been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of growth hormone deficiency patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two year of diagnosis?
  • What percentage of growth hormone deficiency patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated growth hormone deficiency patients?

Geographies: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton

Key analysis provided: Brand/therapy usage across a longitudinal patient sample; newly diagnosed patient analysis; treatment initiation and progression; line of therapy analysis; combination therapy analysis; source of business for recently treated patients; persistency and compliance analysis; product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…